News | Sudden Cardiac Arrest | July 02, 2019

Wearable Defibrillator Offers a Bridge Therapy

Zoll LifeVest buys time for assessment

The Zoll Lifevest Wearable External Defibrillator Offers a Bridge Therapy and buys time for physicians to determine if an implantable defibrillator is needed.

For patients at risk for sudden cardiac arrest (SCA) who are being evaluated for a permanent implantable cardioverter defibrillator (ICD), Zoll offers the LifeVest wearable defibrillator (WCD) as a temporary solution. It allows a physician more time to assess a patient’s long-term arrhythmic risk and make appropriate plans.

The LifeVest is lightweight and easy to wear under a patient’s clothing, allowing them to return to their daily activities while having the peace of mind that they are protected from SCA. The LifeVest continuously monitors the patient’s heart and, if a rapid life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. This device continuously monitors the patient’s heart with dry, non-adhesive sensing electrodes to detect life-threatening abnormal heart rhythms. If a rapid life-threatening heart rhythm (VT or VF) is detected, the device alerts bystanders and delivers a treatment shock to restore normal heart rhythm. The entire event, from detecting a life-threatening arrhythmia to automatically delivering a treatment shock, usually occurs in less than a minute.

The LifeVest is used for a range of patient conditions or situations, including following a heart attack and before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk.

Zoll intregrates this device with the LifeVest Network online patient data management system. It allows clinicians to monitor the patient using downloaded data from a patient’s LifeVest. Clinicians can customize events that generate an alert, or to be notified for a number of events, such as detected arrhythmias, treatments, patient-recorded electrocardiograms (ECGs) and patient use.

 

Other LifeVest Related Content:

Sudden Cardiac Arrest Patient Walks to Ambulance Thanks to Wearable Defibrillator

VIDEO: Demonstration of the LifeVest Wearable Defibrillator System

Diving Deeper Into the Results of the VEST Trial Using Wearable Defibrillators

Wearable Cardioverter Defibrillators Prove Safe for Pediatric Patients

New Technology and Market Challenges Facing Implantable Cardioverter Defibrillators

 

Related Content

HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile
Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia in the NODE-301 trial presented at Heart Rhythm 2020. #heartrhythm2020 #HRS2020
News | EP Lab | May 13, 2020
May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating pati
Medtronic Cobalt and Crome ICD
News | EP Lab | May 12, 2020
May 12, 2020 — Medtronic has received U.S.
The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time. FDA clears, approved, the HeartLight X3 Laser Ablation System to Treat Atrial Fibrillation.

The CardioFocus HeartLight Excalibur Balloon X3 ablation system allows direct visualization of the laser ablation procedure, helping reduce use of X-ray angiography and reducing procedure time.

News | EP Lab | May 12, 2020
May 12, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the next-generation CardioFocus Inc.
EP lab photo from Philips Healthcare
News | EP Lab | April 30, 2020
May 1, 2020 — The Heart Rhythm Society (HRS) has created a COVID-19 Task Force to make recommendations related to edu